Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...
This development marks the latest in a series of strategic investments by the Italian bank to expand its influence in Alpha Bank.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback